Eltrombopag

Drug Profile

Eltrombopag

Alternative Names: 497115; Eltrombopag olamine; Promacta; Revolade; SB-497115; SB-497115-GR

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer GlaxoSmithKline; Novartis; Technische Universitat Dresden
  • Class Benzoates; Hydrazines; Pyrazoles; Small molecules
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aplastic anaemia; Idiopathic thrombocytopenic purpura; Thrombocytopenia
  • Phase II Acute myeloid leukaemia

Most Recent Events

  • 01 May 2017 Novartis suspends patient enrolment in the phase II DELTA trial in Acute myeloid leukaemia (Adjunctive treatment, In the elderly, In adults, Newly diagnosed) in Germany (PO) (EudraCT2014-003150-13)
  • 10 Apr 2017 Novartis plans regulatory submissions for eltrombopag for Aplastic anaemia (First-line therapy) in 2017
  • 31 Mar 2017 Preregistration for Idiopathic thrombocytopenic purpura (In adolescents, In children, In infants) in Canada prior to March 2017 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top